Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAAVATE: RGX-314 in Diabetic Macular Edema
NCT06942520Phase 2Recruiting
- Sponsor
- Sierra Eye Associates
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of surabgene lomparvovec in diabetic macular edema (DME) (3 arms), sponsored by Sierra Eye Associates. Primary endpoint: Mean change from baseline in Best Corrected Visual Acuity at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06942520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942520.